Phase 2 N=62 The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
Smoking Lapse Behavior
Primary: Latency to Initiate Ad-lib Smoking Session — 38.138; 39.416; 19.249 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Response Rate — 0 percentage of participants
Phase 2 N=29 Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Multiple Myeloma
Primary: Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr — 28; 1 Participants — p=<0.05
Phase 2 N=7 Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Recurrent Extragonadal Seminoma · Recurrent Malignant Extragonadal Germ Cell Tumor · Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
Primary: Objective Response Rate — 0; 6; 2; 10 participants
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Phase 2 N=35 Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Adult Acute Myeloid Leukemia
Primary: Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD — 5.7 percentage of participants
Phase 2 N=22 Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
Melanoma
Primary: Safety Measurement - Percentage of Patients Experiencing Serious Adverse Events (SAEs) in the First 4 Months of Treatment. — 9 Participants
Phase 2 N=12 A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Objective Response Rate (PR + CR) Using RECIST — 0 participants
Phase 2 N=126 An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured…
Phase 2 N=20 Multi-day Doses in Prevention of Nausea and Emesis
Myeloma, Plasma-Cell · Lymphoma, Malignant
Primary: Overall Emetic Response: Acute — 5; 9; 1; 0 Participants
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Phase 2 N=414 Sodium Stibogluconate Treatment of Leishmaniasis
Leishmaniasis
Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants
Phase 2 N=10 Safety Evaluation of a Q-fever Vaccine, NDBR 105
Q Fever
Primary: The Adverse Reaction and Occupational Illness Endpoint Measurements in This Q Fever NDBR 105 Vaccine Study Will be Evaluated for All Intent-to-treat Volunteers. — 10…
Phase 2 N=104 Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Adverse Events — 19; 3; 3; 3 participants
Phase 2 N=42 Tandem Auto-Allo Transplant for Lymphoma
Diffuse, Large B-Cell, Lymphoma · Lymphoma, Low-Grade · T-Cell Lymphoma
Primary: Peripheral Blood All-cell Donor Chimerism — 95 percentage of donor-derived elements